Prostate Cancer VL

What are Currently the Best Decision Markers for Biopsy and Re-biopsy of the Prostate? - E. David Crawford

Details
*It is recommended to watch this video in full screen for an optimal viewing experience. What are Currently the Best Decision Markers for Biopsy and Re-biopsy of the Prostate? E. David Crawford, MD University of Colorado Health Science Center SEE RELATED CONTENT Editor-in-chief, Tom Keane, MD interviews E. David Crawford, MD

Guideline of Guidelines: Prostate Cancer Screening - Stacy Loeb

Details
Guideline of Guidelines: Prostate Cancer Screening Stacy Loeb, MD Assistant Professor of Urology and Population Health New York University Click HERE to read the full text article by Dr. Loeb

Screening and Prostate Cancer Mortality: Results of ERSPC

Details
Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up (Lancet 2014) Fritz H. Schröder, MD Click HERE to read the abstract Click HERE to listen to a commentary by the editor-in-chief, Thomas Keane, MD BIOGRAPHY Born in Kassel, 1937, Fritz H. Schröder studied Medicine in Hamburg, Marburg, and at the Univers...

Depressed Men with PCa are Less Likely to Undergo Definitive Therapy and Experience Worse OS

Details
Effect of Depression on Diagnosis, Treatment, and Mortality of Men with Clinically Localized Prostate Cancer Sandip M. Prasad, MD, MPhil Medical University of South Carolina RELATED CONTENT Click HERE to read the abstract Click HERE to watch a video blog from the editor-in-chief, Tom Keane, MD BIOGRAPHY Dr. Prasad received his undergraduate degree with highest honors from Harvard University, a Mas...

Multiparametric Prostate MRI and MRI/Ultrasound Fusion Biopsy

Details
Multiparametric Prostate MRI and MRI/Ultrasound Fusion Biopsy in the Follow-up of Prostate Cancer Progression for Men on Active Surveillance Annerleim Walton-Diaz, MD National Institutes of Health Click HERE to view the presenter's slides from this session Click HERE to read an exclusive report by a UroToday medical writer

Validation of 46-gene CCP RNA Signature for Predicting PCa Death

Details
Validation of a 46-gene Cell Cycle Progression (CCP) RNA Signature for Predicting Prostate Cancer Death Peter T. Scardino, MD, FACS Memorial Sloan Kettering Cancer Center Click HERE to read an exclusive report by a UroToday medical writer. Click HERE to view the poster from this session.

Validation of Genomic Classifier After Radical Prostatectomy

Details
AUA 2014 - Independent Validation of a Genomic Classifier in an at-risk Population of Men Conservatively Managed After Radical Prostatectomy Eric Klein, MD Cleveland Clinic

Predicting Radical Prostatectomy Outcome

Details
Predicting Radical Prostatectomy Outcome: CCP-CR Score Outperforms Primary Gleason Grade Among Men with Clinical Gleason less than 7 who are Upgraded to Gleason 7 Matthew R. Cooperberg, MD, MPH UCSF Medical Center Click HERE to view the poster from this session

Serum Testosterone on Continuous ADT: Is the Level Important?

Details
Serum Testosterone on Continuous ADT: Is the Level Important? Laurence Klotz, MD Click HERE to read an exclusive report by a UroToday medical writer Click HERE to view the poster from this session

Hormones & Radiation for High-Risk PCa+

Details
Hormones and Radiation for High-Risk PCa+ Anthony V. D'Amico, MD, PhD
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe